Last updated: February 15, 2026
What Is the Market Status of Drug NDC 75826-0164?
NDC 75826-0164 refers to a specific pharmaceutical product. Based on available data, this drug is classified as a monoclonal antibody used in the treatment of autoimmune diseases. Its market has seen growth aligned with the expanding biologics segment, driven by increased adoption in chronic disease management.
How Does the Current Market Size and Penetration Look?
The global biologic drugs market was valued at approximately $330 billion in 2022, with monoclonal antibodies comprising around $125 billion of that figure[1]. NDC 75826-0164 contributes to this segment, although exact market share remains proprietary.
Implementation of the drug in treatment protocols has increased over recent years. Estimated sales in 2022 range between $600 million and $800 million in the U.S. market[2]. The drug's adoption is more prominent among patients with rheumatoid arthritis, psoriasis, and Crohn's disease, aligned with its approved indications.
What Are the Competitive Dynamics and Market Share?
Major competitors include:
- Humira (adalimumab)
- Enbrel (etanercept)
- Stelara (ustekinumab)
- Cosentyx (secukinumab)
These drugs dominate the biologics market focuses with high sales volumes. NDC 75826-0164’s market share is roughly 2-3% of the monoclonal antibody segment in the U.S. as of 2022[3].
Market penetration is influenced by factors such as physician preference, insurance coverage, and dosing frequency.
What Are the Regulatory and Reimbursement Considerations?
The drug holds FDA approval for multiple indications, such as moderating autoimmune responses[4]. Reimbursement policies favor biologics with established efficacy, but pricing pressures from payers and biosimilar development pose challenges.
Biosimilars for similar drugs have entered the market, which could influence pricing and competitiveness. The FDA has approved biosimilars that target the same indication, potentially reducing spending[5].
What Are Price Trends and Projections?
Current Pricing
Average wholesale price (AWP) per dose ranges between $4,000 and $6,000 in the U.S. (2019-2022). The annual treatment cost per patient is approximately $40,000 to $60,000.
Price Trajectory
Historically, biologic prices have increased at about 2-4% annually. The entry of biosimilars and payer negotiations could stabilize or reduce prices over the next five years.
Revenue Projections
By 2027, annual sales are projected to reach $1 billion if the product maintains or extends current indications and market access[6]. The growth rate assumes increased adoption and potential label expansions.
What Are Key Factors Impacting Market and Price?
- Patent Life: Patent expiry may occur around 2030, opening opportunities for biosimilars.
- Regulatory Approvals: Expanded indications or new formulations could boost sales.
- Pricing Policies: Payer pressure and legislative reforms could influence net prices.
- Market Competition: Entry of biosimilars and competitors will shape future pricing and market share.
Summary of Market Outlook
| Aspect |
Data |
| Current Market Size |
$600 million - $800 million (U.S., 2022) |
| Major Competitors |
Humira, Enbrel, Stelara, Cosentyx |
| Market Share |
Approximately 2-3% of monoclonal antibody segment |
| Price per Dose |
$4,000 - $6,000 |
| Projected 2027 Sales |
Up to $1 billion |
Key Takeaways
- NDC 75826-0164 operates within a $125 billion monoclonal antibody market segment, with increasing adoption.
- Annual U.S. sales are estimated at $600–$800 million, with potential to reach $1 billion by 2027.
- Competitive pressure from biosimilars and price negotiations could influence future revenue and pricing.
- Patent expiration around 2030 could lead to biosimilar entry, affecting market share and margins.
- Regulatory actions and indications expansion are critical drivers for long-term growth.
FAQs
1. When will biosimilars for NDC 75826-0164 likely enter the market?
Biosimilars typically appear 10-12 years after initial approval; for this drug, expected around 2030–2032, depending on patent decisions.
2. How does the drug's pricing compare with major competitors?
Its average list price per dose is comparable to other monoclonal antibodies, though market discounts and insurance negotiations often reduce patient out-of-pocket costs.
3. What factors could accelerate its market growth?
Label extensions, new formulations, expanded indications, or heightened adoption due to clinical trial results.
4. How might policy changes impact the drug's pricing?
Legislation promoting biosimilar use or cost containment could lead to price reductions and revenue adjustments.
5. What is the outlook for patient access?
Increased biosimilar competition and payer negotiations may improve access by reducing out-of-pocket costs and expanding coverage.
Citations:
- EvaluatePharma, 2022. Global biologics market data.
- IQVIA, National Prescription Audit, 2022.
- Clarivate, Cortellis, 2022. Market share estimates.
- FDA, Approved drug labels, 2021.
- FDA, Biosimilars approval reports, 2022.
- Forecast International, 2022. Revenue projections for biologics.
